MOLN Molecular Partners AG

SWX · CH · Healthcare · Biotechnology · molecularpartners.com

3.250CHF-2.40%Mkt Cap: 142.08M $P/E: —Today

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP03…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap142.08M USD

Enterprise Value71.52M USD

Revenue (TTM)—

Gross Profit-40.59M USD

Net Income (TTM)-70.36M USD

Revenue/Share—

Last Price3.250 CHF

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees134

CountryCH

SectorHealthcare

IndustryBiotechnology

ISINCH0256379097

Valuation

P/E (Trailing)—

P/E (Forward)14.42

PEG—

EV/EBITDA-1.23

EV/Revenue—

P/S—

P/B2.18

EPS (TTM)-1.36

EPS (Forward)0.23

52W Range

2.66045% of range3.960

52W High3.960 CHF

52W Low2.660 CHF

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-76.74%

ROA-60.38%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-58.50M USD

CapEx (TTM)814.89K USD

FCF Margin—

FCF Yield-21.72%

Net Debt-74.06M USD

Net Debt/EBITDA1.28

Balance Sheet

Debt/Equity0.05

Current Ratio7.27

Quick Ratio7.05

Book Value/Sh1.53 CHF

Cash/Share1.77 CHF

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 CHF

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)9.000 CHF

Upside (mean)+176.9%

Target Range3.000 CHF – 15.00 CHF

3.000+176.9% to mean15.00

# Analysts2

Ownership

Shares Out.38.31M

Float20.71M

Insiders8.47%

Institutions43.81%

Technical

SMA 503.374 (-3.7%)

SMA 2003.330 (-2.4%)

Beta0.69

S&P 52W Chg14.58%

Avg Vol (30d)14.78K

Avg Vol (10d)8.88K

Technical Indicators

RSI (14)48.4

MACD-0.0187

MACD Signal-0.0147

MACD Hist.-0.0040

BB Upper3.487 CHF

BB Middle3.344 CHF

BB Lower3.201 CHF

BB Width8.54%

ATR (14)0.1377 CHF

Vol Ratio (20d)1.32x